AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
阿豆学长长ov
发表于 2023-12-26 19:02:07
257
0
0
On December 26th, AstraZeneca announced that it had signed a final agreement on its acquisition proposal for Genxi Biotechnology. This proposed acquisition will add GC012F CAR-T cell therapy to AstraZeneca's cell therapy pipeline, further deepening its layout in the field of cell therapy.
AstraZeneca introduced that GC012F, based on the FasTCAR technology platform, is an innovative BCMA/CD19 dual target autochimeric antigen receptor T cell therapy (CAR-T) in the clinical stage, which is expected to become a new generation treatment plan for multiple myeloma, other types of malignant hematological tumors, and autoimmune diseases (including systemic lupus erythematosus (SLE)).
It is reported that the principle of autologous CAR-T cell therapy is to re edit and modify the patient's own immune T cells to target pathogenic cells for disease treatment. The production and preparation process is complex and time-consuming. The FasTCAR next-day production technology platform of Genxi Biotechnology can not only significantly shorten production time, but also enhance the health status of T cells, which is expected to improve the effectiveness of autologous CAR-T therapy. This technology is also expected to be applied in the treatment of rare diseases in the future.
AstraZeneca's Global Executive Vice President and Head of Research and Development in the Field of Cancer Therapy, Gao Shucan, stated that the company has established CAR-T and TCR-T pipelines for solid tumors. The acquisition of Genxi Biotechnology will further strengthen AstraZeneca's strength in the field of cell therapy. GC012F will help the company accelerate its strategy of laying out cell therapy in the field of blood tumors, and is expected to provide potential treatment options for blood tumor patients with similar differentiated production.
After the acquisition is completed, Genxi Biotechnology will continue to operate as a wholly-owned subsidiary of AstraZeneca in China and the United States.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
- Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
- Cancer company Aravive's US stock market plummeted by over 57% before trading
- Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
- 12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
- Baishime Squibb CAR-T therapy approved by the US FDA
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏
-
【ナスダック中国金龍指数は1%下落した。人気の中概株の多くは下落した】現地時間11月21日、ナスダック中国金龍指数は1%下落し、人気の中概株の多くは下落し、必死に10%超下落し、愛奇芸は7%超下落し、百度は6%近く ...
- 比尔992
- 昨天 11:57
- 支持
- 反对
- 回复
- 收藏